Santacruzamate A (CAY10683) is a natural product obtained from the Panamanian marine cyanobacterium that is reported to be a selective and powerful HDACi for HDAC2.13 CAY10683 has obtained clinical approval due to its immunomodulatory and antiproliferative effects,13 and is consequently utilized for treating breast cancer14 and cutaneous T-cell lymphoma.15 So far, no study has been carried out to examine the role of CAY10683 in CML resistant to IM, and the effects of CAY10683 combined with IM on CML cells resistant to IM remain unclear. Here, HDAC2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.